Evidence map›Paper›PMID 38033273›Full record

ArticleJCO oncology practice2024

Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs.

Morgan R L Lichtenstein, Melissa P Beauchemin, Rohit Raghunathan, Shing Lee, Sahil D Doshi, Cynthia Law, Melissa K Accordino, Elena B Elkin, Jason D Wright, Dawn L Hershman

Abstract read
In one paragraph

Article in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Morgan R L LichtensteinHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-2159-0065
Melissa P BeaucheminDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0003-4058-1586
Rohit RaghunathanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
Shing LeeHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-8413-6869
Sahil D DoshiDivision of Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0261-4829
Cynthia LawHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
Melissa K AccordinoDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0002-4156-7279
Elena B ElkinMailman School of Public Health, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-8833-4213
Jason D WrightDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-6390-825X
Dawn L HershmanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-8807-153X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Training Program in Cancer-related Population SciencesT32CA094061 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NEUGUT, ALFRED I., TERRY, MARY BETH · 2017 to 2021
$1.1M
Delays in Acquisition of Oral Antineoplastic AgentsR21CA242044 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERSHMAN, DAWN · 2020 to 2021
$417k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA242044NCI NIH HHS T32 CA094061
6 · The paper itself

Abstract

purposeOral anticancer drugs (OACDs) have become increasingly prevalent over the past decade. OACD prescriptions require coordination between payers and providers, which can delay drug receipt. We examined the association between insurance type, pursuit of copayment assistance, pursuit of prior authorization (PA), and time to receipt (TTR) for new OACD prescriptions.

methodsWe prospectively collected data on new OACD prescriptions for adult oncology patients from January 1, 2018, to December 31, 2019, including demographic and clinical characteristics, insurance type, and pursuit of PA and copayment assistance. TTR was defined as the number of days from prescription to OACD receipt. We summarized TTR using cumulative incidence and compared TTR by insurance type, pursuit of copayment assistance, and PA activity using the log-rank test.

resultsOur cohort of 1,024 patients was 53% male, and 40% were younger than 65. Twenty-six percent had commercial insurance only, 16% had Medicaid only, and 59% had Medicare with or without additional insurance. Eighty-six percent of prescriptions were successfully received. Across all prescriptions, 69% involved PA activity, and 21% involved the copayment assistance process. In unadjusted analyses, prescriptions involving the copayment assistance process had longer TTR compared with those not involving assistance (log-rank

conclusionThe process for obtaining OACDs is complex. The copayment assistance process and Medicare/commercial insurance are associated with delayed TTR. New policies are needed to reduce time to OACD receipt.

Indexed as

Antineoplastic AgentsNeoplasmsAdultAgedFemaleHumansMaleMedicaidMedicarePrior AuthorizationUnited StatesAntineoplastic Agents

Identifiers

PMID38033273
PMCPMC10827292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.